#Berlin #HealthTech #company #Mika #selected #White #House #initiative
The HealthTech company Mika has prevailed in a selection process and is therefore the only German company to be part of the first cohort of the US government’s new “CancerX Accelerator” program. The CancerX initiative was launched by the White House last year to actively pursue the goals of the so-called “Cancer Moonshot.” The “Cancer Moonshot” aims to reduce the death rate from cancer by at least half over the next 25 years and to improve the quality of life of those affected and their relatives. The startups that have now been selected work with so-called “CancerX Champions” as part of the program. Mika was the only participant to be chosen as a partner by four champions.
The CancerX Accelerator Programm promotes digital innovation in oncology by offering startups the opportunity to collaborate with leading companies in technology, patient care and cancer research. DMika joined CancerX at the beginning of 2024 and is now part of the first group of funded startups. In addition to “C the Signs”, Mika is the only European company in the accelerator program.
Mika wins the selection process
Mika prevailed among more than 100 applicants in a selection process that spanned three rounds of evaluation. The selection was made by CancerX Champions Debiopharm, Reveal HealthTech, UC Davis Health, Atrium, Dell Technologies, Intel, AstraZeneca, AWS and Oncology Ventures and other members of the CancerX community. “It is a great confirmation of our work to be among the first members of this groundbreaking funding program, and especially that we were able to convince four outstanding sponsors to work together. This will enable us to achieve our goal of improving the quality of life and survival rate of cancer patients even more effectively. This is also an important step for our upcoming market entry in the USA,” says Dr. Gandolf Finke, founder and managing director of Mika.
As part of the accelerator program, Mika and the other participants will work with their sponsors over a four-month period and engage with mentors and CancerX members from across the healthcare ecosystem, including investors, provider organizations and oncology experts, to develop their Test and validate solutions. The program is intended to create long-term partnerships and viable growth plans for participants.
“I am confident that the CancerX Accelerator, through its unique collaborative ecosystem, will strengthen the role of digital therapeutics in oncology and accelerate urgently needed patient and physician access to digital treatments to defeat this terrible disease,” sagt Mark Slaughter, Chief Strategy and Growth Officer von Mika.
